Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-059-4 | CAS number: 920-66-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In accordance with the OECD guideline on combined repeated dose and reproductive/developmental toxicity screening test, 2-propanol, 1,1,1,3,3,3-hexafluoro- (PHF) was studied for oral toxicity in rats at doses of 0, 10, 60, and 300 mg/kg/day. Duration of administration was 42 days for males and 42-52 days for females.
As a result, NOAEL of PHF was judged to be 60 mg/kg/day since a death in female, clinical signs attributed to central nervous system depression and anesthetic action, decreased body weight and irritative changes in the gastrointestinal tract (chiefly in duodenal mucosa) were observed in both sexes at 300 mg/kg/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 60 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Additional information
In accordance with the OECD guideline on combined repeated dose and reproductive/developmental toxicity screening test, 2-propanol, 1,1,1,3,3,3-hexafluoro- (PHF) was studied for oral toxicity in rats at doses of 0, 10, 60, and 300 mg/kg/day. Duration of administration was 42 days for males and 42-52 days for females.
As a result, treatment-related changes were chiefly observed at 300 mg/kg. At the dose, clinical signs attributed to central nervous system (CNS) depression and anesthetic action were observed in both sexes, and one of the females died during the delivery following administration on day 24 of gestation. Prior to death, signs of CNS depression were also observed in this dead animal.
In females at 300 mg/kg, body weight and food consumption decreased or tended to decrease in the late of gestation until day 4 of lactation. The body weight of males in this group tended to decrease late in the administration period, but recovered during the recovery period. In addition, food consumption was comparable to that of the control group during the administration period, but it decreased during the recovery period. In the 300 mg/kg group, one male showed erosion of duodenal mucosa and the dead female revealed erosion with hemorrhage in the fundic mucosa and erosion of the duodenal mucosa with hypertrophy of the duodenal glands. According the material safety data sheet, PHF is categorized into corrosive substance. Therefore, erosion in the stomach and duodenal mucosa was considered to be caused by irritability of the test substance.
At 300 mg/kg, hypertrophy of centrilobular hepatocytes was observed in both sexes and liver weight was increased in males at 300 mg/kg. Since there were no fatty degeneration or any increases in liver enzymes indicating liver damage, and it was a reversible change, it was considered to be an adaptive change.
Increased triglyceride was found in the male groups at 60 mg/kg or higher and one female 300 mg/kg. Although relation of the change with the treatment was not clear, it was reversible and not accompanied by any histopathological changes, therefore it was considered not significant.
From the above results, NOAEL for repeated dose toxicity of PHF was judged to be 60 mg/kg/day for males and females based on a death in females, clinical signs attributed to CNS depression and anesthetic action, decreased body weight and irritative changes in the gastrointestinal tract (chiefly in duodenal mucosa) observed in both sexes at 300 mg/kg/day.
Repeated dose toxicity: via oral route - systemic effects (target organ) digestive: duodenum; neurologic: central nervous system
Justification for classification or non-classification
Duration of treatment for repeated dose toxicity study of PHF with rats was about half of 90 days (42 days for males and 42 -52 days for females). Thus, guidance value for STOT classified into Category 2 is considered to be 20 mg/kg/day < ED <= 200 ma/kg/day. In this repeated dose study, effective dose (LOAEL) was concluded to be 300 mg/kg/day. Since the effective dose is above the guidance value, PHF is not classified for STOT.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.